World Health Organization, South-East Asia Regional Office

(1)

Data Sources: Ministries of Health in SEAR Countries.

Published by

Immunization & Vaccine Development

, World Health Organization, Regional Office for South-East Asia, New Delhi

–

110002, India

Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: [email protected], URL:

Vol. 21, Week 44, 2017

Published 06 November 2017

Meetings/ Important events:



Tenth Meeting of the South-East Asia Regional Commission for the Certification of Polio Eradication (SEA-RCCPE), Naypitaw, Myanmar,

23-24 November 2017

**Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 06 November 2017)**

**Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2016* (data as of 06 November 2017)**

La

b

o

ra

to

ry

-c

o

n

fi

rm

ed

E

p

id

em

io

lo

g

ic

a

ll

y-co

n

fi

rm

ed

C

li

n

ic

a

ll

y-co

n

fi

rm

ed

La

b

o

ra

to

ry

-c

o

n

fi

rm

ed

E

p

id

em

io

lo

g

ic

a

ll

y-co

n

fi

rm

ed

Bangladesh 7 418 92 80 5 971 99 100 60 2 491 906 444 209 34 3 334 0 2.53 73 29.10 1.84

Bhutan 221 84 79 166 59 105 46 14 0 0 2 0 160 45 25.38 65 22.20 3.17

DPR Korea 63 100 100 63 100 100 100 0 0 0 0 0 63 0 0.30 0.00 0.00

India3 _{16 200} ₀ ₃₃ _{5 106} ₈₀ ₈₅ ₅₇ _{2 326} _{6 158} ₀ ₆₉₆ _{2 004} _{2 482} _{2 534} _0.23 ₅ _7.92 _2.52

Indonesia4 _{4 793} ₃₈ ₁₀₀ _{3 531} ₉₂ ₇₃ ₂₇ ₉₆₇ ₀ ₀ ₅₅₄ ₀ ₄₉₇ _{2 775} _0.23 _4.53 _2.60

Maldives 62 97 100 62 100 100 69 1 0 0 1 0 59 1 20.40 60 3.46 3.46

Myanmar 1 645 40 88 1 443 99 100 94 994 179 70 3 0 374 25 0.86 14 28.57 0.07

Nepal 713 26 89 232 74 257 84 51 26 21 14 0 571 23 2.47 51 4.24 0.61

Sri Lanka 203 98 89 177 90 100 62 1 0 18 1 0 183 0 1.05 23 62.00 0.42

Thailand 2 381 31 91 2 080 56 96 60 1 281 4 296 23 0 695 82 1.27 28.80 0.42

Timor-Leste 98 100 99 97 100 87 64 0 0 0 3 0 82 13 8.00 31 0.00 2.93

SEAR 33 797 32 62 18 928 87 92 56 8 126 7 273 849 1 506 2 038 8 500 5 498 0.46 10.30 2.25

1

Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases 4

A lso includes the cases fro m enhanced measles case-based surveillance. ND=No data

2

Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases

3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry

* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.

%

s peci mens tes ted for s erol ogy

of s peci mens

recei ved i n the l a bora tory

% s erol ogy res ul ts reported w/i n 4 da ys

of s peci men recei ved a t l a bora tory

Case classification (number)

Reporti ng ra te of di s ca rded

non-mea s l es non-rubel l a ca s es a t the na ti ona l l evel per 100,000 popn

% di s tri cts reporti ng a t

l ea s t 2 di s ca rded

non-mea s l es non-rubel l a

ca s es per 100,000 popn

Mea s l es i nci dence1

per mi l l i on

popn

% s erum s peci mens recei ved a t l a bora tory w/i n 5 da ys of col l ecti on

Rubel l a i nci dence2

per mi l l i on

popn

Mea s l es Rubel l a

D

is

ca

rd

ed

n

o

n

-m

ea

sl

es

n

o

n

-ru

b

el

la

c

a

ses

P

en

d

in

g

c

la

ss

if

ic

a

ti

o

n

Countries

Number of s us pected mea s l es

ca s es % s us pected ca s es wi th a dequa te i nves ti ga ti

on i ni ti a ted

w/i n 48 hours of noti fi ca ti on

% s us pected ca s es wi th s erum s peci mens

col l ected Number of

s erum s peci mens recei ved i n l a bora tory

La

b

o

ra

to

ry

-c

o

n

fi

rm

ed

E

p

id

em

io

lo

g

ic

a

ll

y-co

n

fi

rm

ed

C

li

n

ic

a

ll

y-co

n

fi

rm

ed

La

b

o

ra

to

ry

-c

o

n

fi

rm

ed

E

p

id

em

io

lo

g

ic

a

ll

y-co

n

fi

rm

ed

Bangladesh 4 298 94 87 3 732 100 100 92 619 354 96 165 0 3 064 0 1.96 80 6.85 1.06

Bhutan 149 63 87 127 59 102 47 10 0 0 0 0 60 79 8.05 55 13.42 0.00

DPR Korea 73 100 100 73 100 100 100 0 0 0 0 0 66 7 0.27 0.00 0.00

India3 _{41 617} ₀ ₂₂ _{9 037} ₈₆ ₈₃ ₃₁ _{3 646} _{12 803} ₀ _{1 617} _{7 539} _{6 998} _{9 014} _0.55 ₃ _13.00 _7.24

Indonesia4

8 107 44 100 5 871 98 74 32 2 705 0 0 1 135 0 2 361 1 906 0.94 10.73 4.50

Maldives 11 100 100 11 100 0 0 0 0 0 0 0 11 0 3.22 15 0.00 0.00

Myanmar 587 0 86 503 100 99 97 194 59 21 10 0 303 0 0.59 11 5.33 0.19

Nepal5 _{1 079} ₁₃ ₈₂ ₁ ₁₀₀ ₀ ₁₃₇ ₁₀₂ ₃₁ ₂₂ ₀ ₇₇₂ ₁₅ _2.83 ₅₆ _9.89 _0.81

Sri Lanka 339 63 86 291 88 100 68 64 0 48 1 0 226 0 1.09 27 62.00 0.42

Thailand 1 431 25 87 1 096 61 99 58 695 15 239 7 0 415 60 0.64 14.63 0.11

Timor-Leste 122 75 91 111 100 95 63 2 0 11 9 0 100 0 8.25 46 10.73 7.43

SEAR 57 813 15 42 20 853 91 89 46 8 072 13 333 446 2 966 7 539 14 376 11 081 0.77 11.72 5.63

1

Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases 4

A lso includes the cases fro m enhanced measles case-based surveillance. ND=No data

2_{Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases} 5_{So me Lab data variables no t available.}

3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry

* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.

%

s peci mens tes ted for s erol ogy

of s peci mens

recei ved i n the l a bora tory

% s erol ogy res ul ts reported w/i n 4 da ys

of s peci men recei ved a t l a bora tory

Case classification (number)

Reporti ng ra te of di s ca rded

non-mea s l es non-rubel l a ca s es a t the na ti ona l l evel per 100,000 popn

% di s tri cts reporti ng a t

l ea s t 2 di s ca rded

non-mea s l es non-rubel l a

ca s es per 100,000 popn

Mea s l es i nci dence1

per mi l l i on

popn

% s erum s peci mens recei ved a t l a bora tory w/i n 5 da ys of col l ecti on

Rubel l a i nci dence2

per mi l l i on

popn

Mea s l es Rubel l a

D

is

ca

rd

ed

n

o

n

-m

ea

sl

es

n

o

n

-ru

b

el

la

c

a

ses

P

en

d

in

g

c

la

ss

if

ic

a

ti

o

n

Countries

Number of s us pected mea s l es

ca s es % s us pected ca s es wi th a dequa te i nves ti ga ti

on i ni ti a ted

w/i n 48 hours of noti fi ca ti on

% s us pected ca s es wi th s erum s peci mens

col l ected Number of

(2)

Vol. 21,

Week 44, 2017

Vaccine Preventable Disease Surveillance Bulletin

Page 2

Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2016-2017 (data as of 06 November 2017)

Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2016-2017 (data as of 06 November 2017)

T

o

ta

l

>

9

0 D

a

y

s

3

T

o

ta

l

>

9

0 D

a

y

s

3

Bangladesh

1 437

0

0 1 437

0

2.85

99

100 1 216

0

0 1 130

86

12

2.88

2.68

98

99 Bhutan

11

0

11

0

5.11

73

100

7

0

3

4

1

3.35

1.43

86

100 DPR Korea

105

0

105

0

1.83

98

100

79

0

48

31

17

1.63

0.99

96

100 India

46 500

0

1

15 46 484

0

0 10.60 10.60

87

98 32 010

0

6 28 697 3 307

1 107

8.63

7.74

86

98 Indonesia

1 409

0

0 1 409

0

2.01

86

96 1 018

0

826

192

109

1.71

1.39

83

98 Maldives

2

0

2

0

2.11

0

100

4

0

4

5.00

0.00

50

100 Myanm ar

466

0

466

0

3.38

96

100

300

0

273

27

1

2.63

2.39

97

100 Nepal

455

0

455

0

5.24

96

100

294

0

279

15

3

4.00

3.80

98

100 Sri Lanka

65

0

65

0

1.20

85

98

60

0

52

8

1

1.31

1.13

87

100 Thailand

246

0

246

0

2.04

75

98

158

0

127

31

15

1.62

1.30

70

94 Tim or-Leste

10

0

10

0

1.87

50

80

1

0

1

0

0.22

0.00

0

100 SEAR

50 706

0

1

15 50 690

0

8.38

87

98 35 147

0

6 31 435 3 706

1 270

6.87

6.15

87

98

3

_{90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.}

2016 (Onset)

2017 (Onset)

AFP

Surveillance Indicators

AFP

Surveillance Indicators

Case Classification

1

Annualized

AFP Rates

2

Specim en

A

F

P

C

a

s

e

s

W

il

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

V

a

c

in

e

D

e

ri

v

e

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

4

C

o

m

p

a

ti

b

le

D

is

c

a

rd

e

d

(

N

o

n

-p

o

li

o

A

F

P

)

Pending

A

F

P

R

a

te

Case Classification

1

_{AFP Rates}

2

_{Specim en}

1

_{All countries are using the virologic classification scheme.}

C

o

m

p

a

ti

b

le

D

is

c

a

rd

e

d

(

N

o

n

-p

o

li

o

A

F

P

)

Pending

A

F

P

R

a

te

N

o

n

-P

o

li

o

A

F

P

R

a

te

%

w

it

h

2 s

p

e

c

.,

a

t

le

a

s

t

2

4 h

rs

a

p

a

rt

,

w

/i

n

1

4 d

a

y

s

N

o

n

-P

o

li

o

A

F

P

R

a

te

%

w

it

h

2 s

p

e

c

.,

a

t

le

a

s

t

2

4 h

rs

a

p

a

rt

,

w

/i

n

1

4 d

a

y

s

%

w

it

h

a

n

y

s

p

e

c

im

e

n

A

F

P

C

a

s

e

s

W

il

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

V

a

c

in

e

D

e

ri

v

e

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

4

Country

2

_{AFP rates per 100,000 children aged <15 years using population figures provided by member countries (AFP cases > 15 years of age or missing age information are excluded).}

%

w

it

h

a

n

y

s

p

e

c

im

e

n

4

_{2016 India: One type 2 VDPV (iVDPV=1) [a=ambiguous c=circulating i=immunodeficiency]}

W

il

d

V

a

c

in

e

W

il

d

V

a

c

in

e

V

D

P

V

W

il

d

V

a

c

in

e

<7 Days

>7

days Wil

d

V

a

c

in

e

W

il

d

V

a

c

in

e

V

D

P

V

W

il

d

V

a

c

in

e

<7 Days

>7 days

Bangladesh IPH, Dhaka 8 0 3 0 0 0 0 1 3 0 0 1 0 0 18 0 8 0 0 0 0 5 5 0 0 0 0 0

Bhutan NIH, Bangkok 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0

DPR Korea NPL, Pyongyong 0 0

BJMC, Ahmedabad 258 0 78 0 25 0 0 74 80 1 0 0 0 0 218 0 77 0 0 0 0 59 76 6 0 0 0 0

NIV, Bengaluru 225 0 56 0 24 0 0 67 70 6 2 0 0 0 143 0 54 0 0 0 0 32 43 14 0 0 0 0

ERC, Mumbai 172 0 53 0 13 0 0 52 43 11 0 0 0 0 141 0 48 0 0 0 0 41 35 15 0 0 2 0

SGPGI, Lucknow 311 0 56 0 53 0 0 86 66 16 34 0 0 0 286 0 59 0 0 0 0 98 62 25 41 0 1 0

KIPM, Chennai 98 0 26 0 17 1 0 26 28 0 0 0 0 0 49 0 9 0 0 0 0 27 13 0 0 0 0 0

NCDC, Delhi 231 0 47 0 38 0 0 91 52 3 0 0 0 0 203 0 56 0 0 0 0 85 53 7 0 0 2 0

IoS, Kolkatta 113 0 26 0 18 0 0 35 33 0 1 0 0 0 162 0 54 0 0 0 0 39 51 15 3 0 0 0

CRI, Kasauli 35 0 5 0 7 0 0 11 12 0 0 0 0 0 20 0 11 0 0 0 0 5 4 0 0 0 0 0

1 443 0 347 0 195 1 0 442 384 37 37 0 0 0 1 222 0 368 0 0 0 0 386 337 82 44 0 5 0

Bio Farma, Bandung 18 0 9 0 3 0 0 1 5 0 0 0 0 0 2 0 0 0 0 0 0 2 0 0 0 0 0 0

NIHRD, Jakarta 12 0 4 0 0 0 0 5 3 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0

PHL, Surabaya 13 0 2 0 4 0 0 4 3 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0

43 0 15 0 7 0 0 10 11 0 0 0 0 0 4 0 0 0 0 0 0 3 1 0 0 0 0 0

Myanm ar NHL, Yangon 7 0 1 0 1 0 0 2 3 0 0 0 0 0 5 0 1 0 0 0 0 3 1 0 0 0 0 0

Nepal NIH, Bangkok 6 0 2 0 2 0 0 1 1 0 0 0 0 0 5 0 0 0 0 0 0 3 2 0 0 0 0 0

Sri Lanka MRI, Colombo 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0

Thailand NIH, Bangkok 4 0 0 0 0 0 0 2 2 0 0 0 0 0 5 0 2 0 0 0 0 3 0 0 0 0 0 0

1 513 0 368 0 206 1 0 459 404 37 37 1 0 0 1 259 0 379 0 0 0 0 403 346 82 44 0 5 0

Polio 3

V

a

c

in

e

m

ix

tu

re

N

P

E

V

b

y

P

C

R

N

E

V

Country of

Case ITD Labs

2016 2017

Intratypic Differentiation results Results pending

A

F

P

c

a

s

e

s

re

fe

rr

e

d

fo

r

IT

D

Indonesia Total

TOTAL

N

P

E

V

b

y

P

C

R

N

E

V

N

e

g

a

ti

v

e

India

India Total

Indonesia

N

e

g

a

ti

v

e

A

F

P

c

a

s

e

s

re

fe

rr

e

d

fo

r

IT

D Polio 1 Polio 2 Polio 3

V

a

c

in

e

m

ix

tu

re